The Changing Face of Clinical Trials: Drug-Development Challenges for Small Biopharmaceutical Companies
Small biopharmaceutical companies encounter challenges in designing and implementing clinical development programs. This article discusses the approaches these companies take toward addressing such obstacles..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:376 |
---|---|
Enthalten in: |
The New England journal of medicine - 376(2017), 5, Seite 469 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Jeffrey M Drazen [VerfasserIn] |
---|
Links: |
---|
BKL: | |
---|---|
Themen: |
Clinical trials |
RVK: |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
OLC199114539X |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | OLC199114539X | ||
003 | DE-627 | ||
005 | 20230512152342.0 | ||
007 | tu | ||
008 | 170303s2017 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a PQ20170721 |
035 | |a (DE-627)OLC199114539X | ||
035 | |a (DE-599)GBVOLC199114539X | ||
035 | |a (PRQ)proquest_journals_18646262940 | ||
035 | |a (KEY)0171808820170000376000500469changingfaceofclinicaltrialsdrugdevelopmentchallen | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q DE-101 |
084 | |a XA 10000 |q AVZ |2 rvk | ||
084 | |a 44.60 |2 bkl | ||
084 | |a 44.00 |2 bkl | ||
100 | 0 | |a Jeffrey M Drazen |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Changing Face of Clinical Trials: Drug-Development Challenges for Small Biopharmaceutical Companies |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
520 | |a Small biopharmaceutical companies encounter challenges in designing and implementing clinical development programs. This article discusses the approaches these companies take toward addressing such obstacles. | ||
650 | 4 | |a Research & development--R&D | |
650 | 4 | |a Regulatory approval | |
650 | 4 | |a Pharmaceutical industry | |
650 | 4 | |a Clinical trials | |
650 | 4 | |a Drugs | |
700 | 0 | |a David P Harrington |4 oth | |
700 | 0 | |a John JV McMurray |4 oth | |
700 | 0 | |a James H Ware |4 oth | |
700 | 0 | |a Janet Woodcock |4 oth | |
700 | 0 | |a Richard A Moscicki |4 oth | |
700 | 0 | |a PK Tandon |4 oth | |
773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 376(2017), 5, Seite 469 |w (DE-627)129495220 |w (DE-600)207154-X |w (DE-576)014893169 |x 0028-4793 |7 nnns |
773 | 1 | 8 | |g volume:376 |g year:2017 |g number:5 |g pages:469 |
856 | 4 | 2 | |u https://search.proquest.com/docview/1864626294 |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_168 | ||
912 | |a GBV_ILN_183 | ||
912 | |a GBV_ILN_290 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2219 | ||
912 | |a GBV_ILN_2414 | ||
912 | |a GBV_ILN_2424 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4219 | ||
912 | |a GBV_ILN_4256 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4310 | ||
912 | |a GBV_ILN_4315 | ||
912 | |a GBV_ILN_4320 | ||
912 | |a GBV_ILN_4323 | ||
936 | r | v | |a XA 10000 |
936 | b | k | |a 44.60 |q AVZ |
936 | b | k | |a 44.00 |q AVZ |
951 | |a AR | ||
952 | |d 376 |j 2017 |e 5 |h 469 |